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Abstract 
 
Sleep/wake homeostasis is important for human health. Due to recent changes 
in the environment, the number of patients suffering from sleep disorders such as 
insomnia is increasing by rapid change of human environment. The author conducted 
physiological study for sleep/wake homeostasis to understand relationship between 
environment factors and sleep disorder and analyzed possibility for treatment of sleep 
disorder by natural products. 
The number of patients with sleep disorder is increasing by change of 
environments, such as shift work, jet lug by travel abroad, increase of stress and aging. 
Especially aging and increase of stress can change level of neurotransmitters in the brain 
including serotonin and noradrenaline. For treatment of insomnia, drug-therapy and 
non-drug therapy are used. As drug therapy, benzodiazepine drug, melatonin receptor 
agonist and orexin receptor antagonist was approved based on understanding for 
sleep/wake homeostasis. As non-drug therapy, natural products have been used for 
treatment method for insomnia. The natural products can ameliorate sleep disorder by 
modulation of the effect of neurotransmitters. To understand physiological effects of 
neurotransmitters to important system for sleep/wake homeostasis can provide useful 
information to develop treatment method for insomnia using natural products.  
The author analyzed the effect of neurotransmitters and input pathway for orexin 
neuron because of their impotence in sleep/wake homeostasis. The role of orexin neuron, 
which produce orexin peptides, in sleep/wake homeostasis have been clarified by animal 
and clinical analysis. Orexin neuron deficient mice showed impairment of sleep/wake 
homeostasis and orexin receptor antagonist ameliorate sleep disorder. In this study, the 
effect of neurotransmitters for orexin neurons was analyzed using slice patch clamp 
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methods on transgenic mice expressing green fluorescent protein specifically in orexin 
neuron and fluorescent microscope.  
Serotonin and noradrenaline hyperpolarized membrane potential of orexin 
neuron. Serotonin-induced hyperpolarization was mediated by serotonin 1A receptor. On 
the other hands, noradrenaline-induced hyperpolarization was mediated by alpha 2 
receptor and activation of gamma aminobutyric acid (GABA)-ergic neuron. Moreover, 
immunohistochemical study showed that serotonergic and adrenergic neural terminal was 
located near orexin neurons. Intracerebral administration of serotonin 1A antagonist for 
third ventricle increased locomotor activity in the night. The results indicating change of 
sleep time. The modulation of orexin neurons can be affect animal behavior.  
The target molecule of sleep promoting natural products was analyzed based on 
database analysis and the possibility for modulation of orexin neuron was discussed. 
Valerenic acid, which is activator of GABA receptor, geissoschizine methyl ether, which 
is activator of serotonin 1A receptor, and rosmarinic acid, which can increase production 
of noradrenaline, is reported as sleep promoting natural products. These natural products 
can be considered to suppress orexin neuron activity based on the effect of 
neurotransmitters on orexin neuron. The results of this research can provide useful 
information for understanding the mechanism of action of natural products and 
development of new treatment method for sleep disorder using drug and natural products. 
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Chapter 1 Introduction 
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1.1 Sleep disorders and the environment 
 Sleep/wake homeostasis is important for human health. Due to recent changes 
in the environment, the number of patients suffering from sleep disorders such as 
insomnia is increasing. In the United States, about half of patients have problems with 
sleep. Sleep disorders are caused by several environmental factors such as the increase 
of shift work; jetlag induced by increased travel abroad; aging [1]; and long working 
hours, which can cause stress, [2]. 
The number of patients with insomnia has increased over the past ten years. 
Sleep disorders can be a cause of other diseases such as diabetes because of disturbance 
to the endocrine system [3]. Insomnia is also associated with the risk of dementia and 
myocardial infarction [4, 5]. Non-alcoholic fatty liver disease can also be caused by 
disturbances in sleep/wake homeostasis [6]. 
 In the development of sleep disease triggered by the environment, stress and 
aging are important factors. Recent rapid changes in one’s environment cause stress and 
aging and affect various brain systems. For example, stress decreases serotonin [7] and 
noradrenaline (NA) [8] production. Aging also decreases serotonin and noradrenaline. 
To understand the physiological changes induced by rapid environmental changes, 
studies focused on brain neurotransmitters are important. 
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Fig. 1.1 Schematic of sleep disorders affected by environmental changes 
(Pictures from https://ja.wikipedia.org) 
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1.2 Epidemiology of insomnia 
 Insomnia is characterized by long sleep latency, frequent nocturnal awaking. 
Sleep disorder have following characteristics: (i) difficulty in falling asleep despite 
adequate opportunity and circumstance to sleep: (ii) impairment of sleep is associated 
with daytime distress: (iii) sleep difficulty occurs at least 3 times per week and has been 
a problem for at least 1 month [9].  
 Large number of patients were suffered in all over the world. Based on 
Diagnostic and Statistical Manual of Mental Disorder-IV classification, which is 
representative criteria for diagnosis of sleep disorder in the world, the preference is 
estimated from 4.4% to 6.4 %[10]. The number of patient with insomnia is increased 
twofold in Japan [11]. Sleep disorder is big problem all over the world. 
 
1.3 The use of natural products for insomnia  
 Complementary medicine is widely used to treat insomnia as it is a common 
disease with symptoms recognizable to patients. In Japan, several kinds of supplements 
are used for the induction of sleep. For example, the amino acid glycine has been used 
to induce sleep [12].  
 Throughout history, several kinds of natural products have been used for the 
treatment of insomnia (Fig. 1.2). In Europe, herbal medicines such as extract of valerian 
and St John’s wort were used for the treatment of sleep disorders [13] [14]. In Japan, 
herbal medicine has long been utilized. For example, yoku-kan-san and Suan Zao Ren 
Tang can be used for insomnia [15] [16]. Kava, a Polynesian plant, can induce sleep in 
humans and has been used for insomnia [13]. Several compounds are considered the 
active components (Fig. 1.3). 
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 According to recent research, the active components of herbal medicines and 
the target molecules of these herbal medicines have been identified. The possible 
modulation of orexin neurons by these molecules is discussed in Chapter 4, based on 
experimental data about receptor subtype expression in orexin neurons and reported 
information for the target molecules of herbal medicine.  
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Fig. 1.2 Natural products with sleep-promoting effects 
(Pictures from https://ja.wikipedia.org)  
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Fig. 1.3 The active components of natural products 
(Pictures from https://ja.wikipedia.org) 
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1.4 Current treatment methods for insomnia 
 For the treatment of insomnia, several kinds of drugs have been developed. The 
first were barbiturates. However, barbiturates are not used for insomnia now because of 
their adverse effects such as low lethal dose, residual sedation tolerance, and 
dependence. As a tolerable treatment option for insomnia, benzodiazepine (BZD) 
receptor agonists have been developed. BZD agonists modulate the activity of the 
gamma aminobutyric acid (GABA) A receptor [17]. Recently, additional drug types 
were approved by the food and drug administration (FDA). One is a melatonin receptor 
agonist. The other is an orexin receptor antagonist [18]. Both the orexin and melatonin 
systems are important for the modulation of sleep/wake homeostasis. Melatonin is 
produced in the pineal gland of the hypothalamus. Orexin is produced by the lateral 
hypothalamic area (LHA) of the hypothalamus. 
 
1.5 The orexin system for sleep/wake homeostasis 
 To develop effective treatment methods, a deep understanding of the neural 
mechanism of sleep/wake homeostasis is needed. Sleep/wake homeostasis is regulated 
by complex neural networks. Through recent advances in technology for neuroscience 
and molecular biology, the molecular mechanism of insomnia has been clarified. The 
role of the orexin system has been clarified over the past 20 years. Orexin was identified 
as the ligand of an orphan G protein coupled receptor (GPCR). Orexins contain two 
peptides derived from one precursor prepro-orexin. Orexin A is a 28 amino acid peptide 
and orexin B is a 32 amino acid peptide. Orexin peptides bind to orexin receptor 1 
(OX1R) and orexin receptor 2 (OX2R), which belong to the GPCR family. Orexin A 
preferentially binds to OX1R. On the other hand, orexin B binds equally to both OX1R 
and OX2R [19]. Orexin neuron terminals innervate wide regions of the brain. Dense 
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projections are observed in serotonergic and adrenergic nuclei, which are involved in 
sleep/wake homeostasis (Fig. 1.4).  
 The role of the orexin system in sleep/wake homeostasis has been clarified 
using Tg/KO mice. OX2R KO mice showed fragmentation of the sleep/wake cycle [20]. 
Orexin/Ataxin-3 mice, which express neurodegenerative peptide ataxin-3 specifically in 
orexin neurons, also showed fragmentation of the sleep/wake cycle [21]. Moreover, a 
dog strain showing disruption of the sleep/wake cycle was found to have a mutation the 
in OX2R gene [22]. In human patients of narcolepsy, which is a severe sleep disorder 
with fragmentation of the sleep/wake cycle, there is a decrease in orexin peptides in the 
cerebrospinal fluid [23]. Based on this information, the orexin system plays an 
important role in sleep/wake homeostasis. 
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Fig. 1.4 The orexin system 
Orexins are produced in orexin neurons in the hypothalamus and secreted to various 
brain regions to maintain the awake state. 
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1.6 Analysis of the regulation of the orexin system to understand the mechanism of 
natural products with sleep promoting effects  
 Orexin neurons have a key role in sleep/wake homeostasis in spite of 
their limited numbers. Compounds that can modulate the neuronal activity of orexin 
neurons can be an effective method for treatment of sleep disorders.  
 Sleep disorders are associated with environmental factors such as stress and 
aging. In this study, we focused on the effect of neurotransmitters associated with stress 
and aging. In Chapter 2, the responsiveness of orexin neurons to neurotransmitters was 
analyzed using the slice patch clamp method. Moreover, the receptors involved in the 
responses were analyzed. In Chapter 3, the role of serotonergic and adrenergic 
modulation of orexin neurons was analyzed to understand their physiological 
importance. In Chapter 4, the possibility for modulation of orexin neurons by 
sleep-promoting natural products was analyzed by database analysis to consider the 
possible modulation of orexin neurons via receptors expressing in orexin neurons (Fig. 
1.5).  
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Fig. 1.5 The design of the study 
 The orexin system is a key system for sleep/wake homeostasis. The effect of 
neurotransmitters on orexin neurons and how this can be changed by environmental 
factors was evaluated (Chapter 2). The physiological role of this modulation was 
clarified to understand the importance of serotonergic and noradrenergic regulation 
(Chapter 3). The possible treatment of sleep disorders by natural products was evaluated 
by database analysis (Chapter 4).  
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Chapter 2 Electrophysiological properties of 
orexin neurons 
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2.1 Introduction 
 Changes to the human environment have an important role in the recent 
increase in sleep disorders. Human environmental changes such as an increase in stress 
and aging cause changes in neurotransmitter levels in the brain.  
 In this chapter, the author focused on the effect of the neurotransmitters 
serotonin and noradrenaline, which can be affected by stress and aging, on orexin 
neurons. The levels of serotonin and noradrenaline were decreased in stress conditions 
[24]. To understand the role of neurotransmitters in sleep/wake homeostasis, their effect 
on orexin neurons can provide useful information because of the importance of orexin 
neurons to sleep/wake homeostasis. 
Orexin neurons, which produce the wake-promoting neurotransmitters orexins, 
are located in the LHA, which is traditionally known as a feeding center [25]. The 
importance of orexin neurons in sleep/wake homeostasis was confirmed by studies 
using rodent models and clinical samples. For example, the ablation of orexin neurons 
via expression of a human ataxin-3 fragment with an elongated polyglutamyl stretch 
under control of the human prepro-orexin promoter caused fragmentation the of 
sleep/wake cycle in mice and rats [26] [21]. The selective activation of orexin neurons 
via selective expression of melanopson, which activates neurons in the presence of blue 
light, caused wakefulness [27]. On the other hand, the selective inhibition of orexin 
neurons by extrinsic receptor expression and ligand treatment caused an increase in 
slow wave sleep [28].  
 Since the activity of orexin neurons can modulate sleep/wake homeostasis, 
information about intrinsic factors modulating orexin neurons is important. While ex 
vivo electrophysiological analysis is effective to understand the responsiveness of 
neurons to neurotransmitters, it has been difficult to identify orexin neurons in slice 
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samples because the LHA contains several kinds of non-orexin neurons, such as 
melanin-concentrating hormone (MCH) neurons, and orexin neurons are sparsely 
distributed [29]. 
 In orexin neurons, the transcription of prepro-orexin gene is mediated by a 
specific promoter region. Orexin neuron-specific gene expression can be induced using 
this promoter. To identify orexin neurons, orexin neuron-specific enhanced green 
fluorescent protein (EGFP)-expressing mice (orexin/EGFP mice) were developed to 
conduct electrophysiological analysis of orexin neurons [30]. 
  In this study, we evaluated the effects of neurotransmitters that can be affected 
by environmental change on orexin neurons. The author identified that GABA, 
serotonin, and NA receptor agonists suppress the activity of orexin neurons. 
 
2.2 Materials and methods 
 
2.2.1 Animal usage 
All experimental procedures involving animals were approved by the University 
of Tsukuba Animal Resource Center and were in accordance with National Institutes of 
Health guidelines. All efforts were made to minimize animal suffering or discomfort and 
to reduce the number of animals used.  
 
2.2.2 Slice preparation 
Male and female orexin/EGFP mice, 3-4 weeks old, in which the human 
prepro-orexin promoter drives expression of EGFP (lines E2 and E7) [30], were used for 
experiments. The mice were deeply anesthetized with fluothane (Takeda, Osaka, Japan) 
and then decapitated. The brains were isolated in ice-cold bubbled (100% O2) 
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physiological solution containing the following (in mM): 140 choline Cl, 2 KCl, 0.1 
CaCl2, 1.9 MgCl2, 10 HEPES, and 10 glucose, pH 7.4 with NaOH; or in sucrose solution 
(in mM: 234 sucrose, 2.5 KCl, 1.25 NaHPO4, 10 MgSO4, 0.5 CaCl2, 26 NaHCO3, and 10 
glucose). Brains were cut coronally into 300 μm slices with a microtome (VTA-1000S; 
Leica, Nussloch, Germany). Slices containing the LHA were transferred to an incubation 
chamber filled with extracellular solution containing the following (in mM): 140 NaCl, 2 
KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.4, with NaOH at room 
temperature (24°C –26°C) for at least for 1 hr.  
 
2.2.3 Identification of EGFP-expressing orexin neurons by fluorescent microscopy  
For electrophysiological recordings, the slices were transferred to a recording 
chamber (RC-27L; Warner Instruments, Hamden, CT) at room temperature on a 
microscope stage (BX51WI; Olympus Optical, Tokyo, Japan). The slices were 
superfused with room-temperature bubbled (100% O2) extracellular solution at a rate of 2 
ml/min using a peristaltic pump (Dynamax; Rainin, Oakland, CA).  
The fluorescence microscope was equipped with an infrared camera (C2741-79; 
Hamamatsu Photonics, Hamamatsu, Japan) for infrared differential interference contrast 
imaging and a charge-coupled device camera (IKTU51CU; Olympus Optical) for 
fluorescent imaging. Each image was displayed separately on a monitor (Gawin; EIZO, 
Tokyo, Japan) and used to identify neurons expressing EGFP. 
 
2.2.4 Electrophysiological recordings 
Patch pipettes were prepared from borosilicate glass capillaries (GC150-10; 
Harvard Apparatus, Holliston, MA) with a micropipette puller (P-97; Sutter Instruments, 
Pangbourne, UK). The pipettes were filled with an internal solution containing the 
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following (in mM): 145 KCl, 1 MgCl2, 1.1 EGTA-Na3, 10 HEPES, 2 MgATP, 0.5 NaGTP, 
and 2 Lucifer yellow, pH 7.2 with KOH. Osmolarity of the solution was checked by a 
vapor pressure osmometer (model 5520; Wescor, Logan, UT). The osmolality of the 
internal and external solutions was 280–290 and 320–330 mOsm/l, respectively. 
Pipette resistance was 4–10 MΩ. The series resistance during recording was 10–
25 MΩ and was not compensated. Recording pipettes were advanced toward individual 
cells in the slice while under positive pressure. After confirmation of tight seals (0.5–1.0 
GΩ) by release of positive pressure, the membrane patch was ruptured by suction, 
Membrane current and potential were monitored using an Axopatch 200B patch-clamp 
amplifier (Axon Instruments, Foster City, CA). Current pulse was applied to the cell at 
duration of 200 msec at 20 pA steps at 2-sec intervals to monitor membrane conductance. 
The reference electrode was an Ag-AgCl pellet immersed in extracellular 
solution. All current-clamp recordings were made in Axopatch 200B fast mode. The 
membrane capacitance was calculated by dividing the time constant by the input 
resistance. Input resistance was calculated from the slope of the current-voltage 
relationship. The output signal was low-pass filtered at 5 kHz and digitized at 10 kHz. In 
the cell-attached and inside-out single-channel recording, the recorded signals were 
filtered at 2 kHz and digitized at a sampling rate of 10 kHz. Data were recorded on a 
computer through a Digidata 1322A analog-to-digital converter using pClamp 8.0.1 
software (Axon Instruments). The trace was processed for presentation using Origin 6.1 
(Microcal Software, Northampton, MA) and Canvas 8.0 (Deneba Systems, Miami, FL) 
software.  
 
2.2.5 Drugs 
The drugs used were tetrodotoxin (TTX), barium chloride (Wako, Osaka, Japan), 
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serotonin, lucifer yellow dipotassium salt, WAY100635, and 8-OH-DPAT, adrenaline, 
NA, dopamine (DA), idazoxan, carbachol (CCh), (2R)-amino-5-phosphonopentanoate 
(AP-5), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), UK-14304 and SKF-96365 
(Sigma, St. Louis, MO). In the electrophysiological experiments, drugs were dissolved in 
extracellular solution and applied by either bath application or local application through a 
thin polyethylene tube positioned near the cells being recorded. 
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2.3 Results 
 
2.3.1 Detection of orexin neurons in slice conditions 
 To detect orexin neurons, orexin/EGFP mice were used. EGFP-expressing 
orexin neurons were easily identified under fluorescent microscopy and charge-coupled 
device (CCD) camera. About 80% of orexin neurons expressed EGFP and ectopic 
expression was not observed (Fig. 2.1). 
 Basic electrophysiological properties were measured by whole cell patch clamp. 
There was no significant difference between EGFP-expressing orexin neurons and 
non-EGFP expressing neurons (Table 2.1). 
  In slices, action potential firing was observed after current injection. Some of the 
orexin neurons showed burst firing. Generation of action potentials was suppressed by 
treatment with TTX (Fig. 2.2).  
 To evaluate adaptations of firing, the relationship between injected current and 
firing frequency was measured. Correlation between injected current and firing frequency 
was observed but adaptation was not. 
 To understand membrane properties, passive membrane properties were 
measured (Fig. 2.3). By injecting hyperpolarizing current, the activation of ion channels 
was observed. Cyclic nucleotide-gated ion channels are known to be involved in 
hyperpolarization-induced current. Hyperpolarization-induced current was inhibited by 
ZD7288, which is a cyclic nucleotide-gated channel inhibitor. 
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Fig. 2.1 Detection of orexin neurons under the fluorescent microscope.  
Fluorescence (left) and IR-DIC (right) images of EGFP-expressing orexin neurons. 
Scale bar: 20 μm. 
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Table 2.1 Comparison of electrical properties of orexin neurons and non-orexin neurons 
 
 EGFP-expressing orexin 
neurons (n = 36) 
Non-EGFP-expressing 
neurons (n = 23)  
Resting membrane 
potential (mV) 
−60.5 ± 5.9 −65.3 ± 7.9 
Spontaneous firing (Hz) 5.5 ± 3.9 5.8 ± 7.4 
Input resistance (MΩ) 390 ± 110 310 ± 220 
Threshold (mV) −30.5 ± 8.9 −39.4 ± 6.0 
Peak (mV) 37.1 ± 8.6 33.6 ± 12.3 
Afterhyperpolarization 
(mV) 
−59.3 ± 6.2 −59.1 ± 6.7 
dV/dt Rise (mV/ms) 132.1 ± 41.3 153.7 ± 50 
dV/dt Fall (mV/ms) 79.9 ± 25.4 101.2 ± 37.3 
Duration of half amplitude 
(msec) 
0.76 ± 0.17 0.65 ± 0.23 
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Fig. 2.2 Active membrane properties of orexin neurons  
A, The shape of the action potential of orexin neurons. B, Spontaneous action potentials 
in orexin neurons. Some orexin neurons showed a bursting firing pattern. C, Recordings 
of membrane potential response to a series of 100 ms current steps (in 20 pA increments) 
from resting potential (−60 mV) in the absence (left) or presence (right) of TTX (1 μM). 
D, E, Relationship between injected current and firing frequency. F: Inter-firing interval 
between events at different current intensities. 
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Fig. 2.3 The presence of hyperpolarization-activated current in orexin neurons 
A, Response to a series of 200 ms current steps (from −200 pA to −20 pA increments) 
from resting potential (−60 mV). The arrow shows an action potential triggered via 
activation of hyperpolarization-induced current. B. I-V relationship. The instantaneous 
potential (open circle in A) and steady state potential (closed circle in A) are plotted. C, D 
The effect of ZD7288. After 10 min treatment with ZD 7288, hyperpolarization-induced 
channel activity was abolished. 
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2.3.2 The effects of glutamatergic and GABAergic neurotransmitters 
 To evaluate glutamatergic and GABAergic regulation, 
α-Amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA), 
N-methyl-D-aspartate (NMDA) and muscimol were applied to orexin neurons. AMPA 
and NMDA depolarized orexin neurons and muscimol hyperpolarized orexin neurons 
(Fig. 2.4). Orexin neurons express AMPA- and NMDA-type glutamate receptors and 
GABAA receptors.  
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Fig. 2.4 The effect of glutamate receptor and GABA receptor agonists on orexin neurons 
A, B: The effects of the glutamate receptor agonists AMPA and NMDA. Membrane 
potential was set to -60 mV by current injection before compound application. C: The 
effect of a GABA receptor agonist. Membrane potential was set at −45 mV by current 
injection.   
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2.3.3 The effect of monoaminergic, cholinergic, and adrenergic neurotransmitters 
 To understand the regulation of orexin neurons by monoaminergic and 
cholinergic system, serotonin, NA, and CCh, which is cholinergic agonist, were applied 
to orexin neurons (Fig. 2.5). Serotonin (100 μM) and NA (100 μM) strongly 
hyperpolarized orexin neurons. In the presence of TTX (1 μM), NA and serotonin 
hyperpolarized the membrane potentials to −14.6 ± 1.5 mV (n = 6) and −15.5 ± 4.5 mV (n 
= 5), respectively. 
On the other hand, CCh depolarized orexin neurons. In the presence of TTX (1 
μM), CCh (100 μM) depolarized the membrane potential to 9.0 ± 1.1 mV (n = 5) when the 
membrane potential was initially set at −60 mV. Atropine (10 μM), an antagonist of the 
metabolic type of acetylcholine receptor (muscarinic receptor), abolished this effect 
completely, suggesting that muscarinic receptors are involved in this response (data not 
shown). The effect of acetylcholine (100 μM) on orexin neurons was the same as that of 
CCh in the presence of TTX (n = 2). 
Orexin neurons express the inhibitory type of serotonin and NA receptors and 
the excitatory type of cholinergic receptors.  
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Fig. 2.5 The effects of monoaminergic and cholinergic neurotransmitters on orexin 
neurons 
A: The effect of serotonin (100 μM). B: The effect of NA (100 μM). C: The effect of CCh 
(100 μM). The membrane potential was set at −45 mV (serotonin and NA) and −60 mV 
(CCh) by current injection. Experiments were performed in the presence (upper) or 
absence (lower) of TTX (1 μM).  
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2.3.4 The mechanism of suppression by serotonin 
 To understand the mechanism of regulation of orexin neurons by serotonin, 
detailed electrophysiological analysis was conducted. 
 All EGFP-positive neurons (orexin neurons) tested were hyperpolarized by 
serotonin (n = 81), whereas EGFP-negative neurons in the same area (non-orexin neurons 
and probably a few orexin neurons, because the EGFP fluorescence of 20% of orexin 
neurons was under the detection limit) showed a variety of responses to serotonin: 33% of 
the neurons (23 of 70) showed hyperpolarization, 20% (14 of 70) showed depolarization, 
and 47% (33 of 70) showed no effect [31]. Serotonin hyperpolarized orexin neurons in a 
concentration-dependent manner. Emax was 32.0 ± 1.0 mV and IC50 was 0.87 μM (n = 4–
6).  
A reduction in membrane resistance was observed following treatment with 
serotonin (Fig. 2.6). The effect of serotonin was measured in the presence of 
hyperpolarizing current injection. Serotonin hyperpolarized orexin neurons with a 
reduction in membrane resistance. Membrane resistance was decreased from 551 ± 44 to 
328 ± 32 MΩ by treatment of serotonin (100 μM). 
 The reversal potential was estimated by the I-V relationship by current injection. 
The estimated reversal potential was −111.2 ± 7.7 mV. The reversal potential was shifted 
to −74.7 ± 1.6 mV when extracellular potassium concentration was shifted to 10 mM. 
Both reversal potentials were similar to the reversal potential of the potassium ion. 
Rectification properties were analyzed by changing the holding potential. Inward 
rectification was observed. These results suggest that inward rectifier potassium channels 
were activated by serotonin. 
 To identify the serotonin receptor subtypes that have important roles in the 
regulation of orexin neurons, subtype-selective receptor agonist were used (Fig. 2.8). The 
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serotonin 1A receptor selective agonist, 8-OH-DPAT mimicked the effect of serotonin. 
The potency of 8-OH-DPAT was comparable with serotonin; the IC50 value was 0.3 μM 
(n = 4–7). On the other hand, the hyperpolarization of orexin neurons by serotonin was 
suppressed by pre-treatment with WAY-100635, a serotonin 1A receptor selective 
antagonist. Pretreatment of slices with 1, 10, and 100 nM WAY100635 for 2 min inhibited 
10 μM serotonin-induced hyperpolarization to 80% ± 8%, 60% ± 10%, and 4% ± 4%, 
respectively, compared with the results before antagonist treatment. 
 Immunohistological analysis was conducted to check the expression of receptors 
(Fig. 2.8). Serotonin 1A receptor-immunoreactive cells were observed in the lateral 
hypothalamus. Co-localization of orexin immunoreactivity and serotonin 1A receptor 
immunoreactivity was confirmed. 
 For detailed analysis of activated potassium channels, single channel recordings 
were conducted (Fig. 2.9). Single channel recordings in cell attached mode were 
conducted in the presence or absence of serotonin (1 μM). To test the effect of serotonin, 
serotonin was backfilled in a glass pipette to detect the effect of serotonin in a 
time-dependent manner. Single channel current was increased in the serotonin-containing 
condition. The average single channel current was 3.4 pA. The single channel 
conductance was calculated by changing pipette voltage and estimated as 33.8 ± 4.3 pS, 
which is similar to the conductance of G-protein activated potassium channels. 
 To test the pharmacological properties of the ion channels, the effect of Ba2+, 
which is known to suppress G protein-coupled inwardly-rectifying potassium channel 
(GIRK), was assessed. Ba2+ suppressed serotonin-induced hyperpolarization in a 
dose-dependent manner (Fig. 2.10).  
 From these data, suppression of orexin neuron activity was mediated by 
serotonin 1A receptors and subsequent activation of GIRK.   
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Fig. 2.6 The concentration dependency of serotonin-induced hyperpolarization 
A: The decrease in membrane resistance by treatment with serotonin (10 μM). Input 
resistance was monitored by the change in membrane potential generated by injection of a 
current pulse (−20 pA, 500 msec, 0.1 Hz). B, The concentration dependence of the 
serotonin response. IC50 was 0.87 ± 0.18 μM. Values are mean ± S.E. (n = 4–7). 
 
  
A B 
Serotonin (µM) 
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Fig. 2.7 Serotonin increases potassium conductance 
A, Recordings of membrane potential in response to a series of 100 ms current steps (in 
20 pA increments, −200 pA to 180 pA) from resting potential (−60 mV). Left, absence of 
serotonin. Right, presence of serotonin (10 μM). B, Current-voltage relationship. 
Estimated reversal potential was −107.3 mV. C, The shift in reversal potential by the 
change in extracellular potassium concentration. D, IV relationship in voltage clamp 
conditions. Serotonin (10 μM) was applied at each holding potential. N = 4–7, mean ± 
S.E. 
A 
B C 
D 
Serotonin 10 µM 
●Serotonin 10 µM 
〇Control 
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Fig. 2.8 Serotonin 1A receptor expression in orexin neurons 
A, Dose relationship of serotonin 1A receptor agonist, 8-OH DPAT. All responses were 
normalized to 10 μM serotonin applied before treatment. IC50 was 0.30 ± 0.002 μM. 
Mean ± S.E. n = 4–7. B, Inhibition of serotonin-induced hyperpolarization by serotonin 
1A receptor antagonist WAY 100635. Mean ± S.E. n = 5–14. C, Immunohistological 
analysis for serotonin 1A receptor. Left, immunoreactivity for orexin (green, Alexa 488). 
Middle, immunoreactivity for serotonin 1A receptor (red, Alexa 594). Right, merged 
image.  
A B 
C 
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Fig. 2.9 Single channel characteristics of the channels activated by serotonin 
A, Cell-attached recording with control pipette. B, Cell attached recordings with 
serotonin (1 μM) backfilled pipette. C, Histograms of single channel recordings. Left, 
absence of serotonin. Right, presence of serotonin (1 μM). 
A 
B 
C 
Serotonin 1 µM Control 
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Fig. 2.10 The effect of inhibition of inward rectifier potassium channel 
A, Inhibition of serotonin-induced hyperpolarization via Ba2+. Input resistance was 
monitored by injection of current pulse (-20 pA, 500 msec, 0.1 Hz). B, Relative inhibition 
of the effect of serotonin. Mean ± S.E. *: p  0.05.  
A 
B 
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2.3.5 The mechanism of suppression of orexin neurons by NA 
 To clarify the receptors implicated in the response to NA, detailed analysis was 
conducted. In current clamp mode, NA application hyperpolarized the membrane 
potential of all EGFP-positive neurons (orexin neurons) tested in the presence or absence 
of TTX (n = 80).  
In the presence of TTX, NA (30 μM) application significantly decreased 
membrane resistance to 47% of control values; the membrane resistance of orexin 
neurons before and after NA application was 613.1 ± 24.8 and 289.6 ± 16.9 MΩ (n = 5), 
respectively (Fig. 2.11). At a holding potential of–60 mV under voltage clamp, NA (30 
μM) induced an outward current in orexin neurons in the presence of TTX. NA 
hyperpolarized orexin neurons in a concentration-dependent manner. Emax was 17.3 ± 0.5 
mV at 100 μM, IC50 was 6.7 ± 0.7 μM (n = 4–6).  
Adrenaline also induced hyperpolarization of orexin neurons in a 
concentration-dependent manner (Fig. 2.11); the effect was more potent than that of NA 
(Emax was 24.2 ± 0.4 mV at 30 μM; IC50 was 2.4 ± 0.2 μM, n = 4–6). 
On the other hand, DA showed hyperpolarization at a higher concentration than 
adrenaline and NA (Emax = 17.5 ± 0.6 mV, IC50 = 141.5 ± 21.9 μM, n = 4–6). 
 To identify the adrenergic receptor subtype, the effect of selective adrenergic 
receptor antagonists was evaluated (Fig. 2.12). Idazoxan, which is an α2AR antagonist, 
suppressed NA (30 μM)-induced hyperpolarization. Pretreatment of slices with 0.01 and 
0.1 μM idazoxan for 1.5 min inhibited NA-induced hyperpolarization to 65.5% ± 10.7% 
(n = 4) and 27.0% ± 15.8% (n = 6), respectively, compared with the values before 
antagonist treatment. On the other hand, UK-14304, which is an α2AR agonist, mimicked 
NA-induced hyperpolarization. 1 μM and 10 μM of UK14304 hyperpolarized orexin 
neurons by 38.3% ± 8.0% (n = 4) and 72.1% ± 6.3% (n = 4), respectively, compared with 
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prior application of NA (30 μM). Propranolol, which is a beta adrenergic receptor 
antagonist, did not suppress the effect of NA.  
We also found that NA induced a slight depolarization of orexin neurons in the 
presence of 1 μM idazoxan. NA at concentrations of 1, 10, and 30 μM induced 
depolarizations of 1.9 ± 0.9, 12.0 ± 2.5, and 17.5 ± 3.0 mV (n = 6), respectively, when 
membrane potential was adjusted to −70 mV before the experiment. NA-induced 
depolarization was eliminated by co-application of the selective α1AR antagonist 
prazosin (n = 6, Fig. 2.12).  
 The effect of Ba2+ on NA-induced hyperpolarization was examined to identify 
the ion channels involved. Ba2+ (3–30 μM) inhibited NA-induced hyperpolarization in a 
dose-dependent manner. The reversal potentials of NA with 2 mM potassium and 10 mM 
potassium were −110.2 ± 5.9 mV (n = 5) and –66.6 ± 4.9 mV (n = 5), respectively. The 
slope of the reversal potential values for a 10-fold change in extracellular potassium ion 
was 43.6 mV.  
Based on these results, hyperpolarization by NA is mediated by α2AR and 
subsequent activation of inward rectifier potassium channels.  
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Fig. 2.11 Hyperpolarization of orexin neurons by catecolamine 
A, Hyperpolarization by NA. Experiment was conducted in current clamp mode without 
TTX (upper), with TTX (middle), and in voltage clamp mode (lower). B, 
Hyperpolarization by DA. Current clamp mode with TTX (upper). Voltage clamp mode  
(lower). Membrane potential was set at -60 mV in both current clamp mode and voltage 
clamp mode. C, Concentration relationship to the effect of catecholamine.   
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Fig. 2.12 The effect of adrenergic receptor antagonists on NA induced hyperpolarization 
Recordings were conducted in current clamp mode. A, Idazoxan, an ɑ2AR antagonist, 
suppressed hyperpolarization induced by orexin. B, The effect of adrenergic antagonists 
on NA-induced hyperpolarization. C, The effect of adrenergic agonist on the membrane 
potential of orexin neurons. B, C, mean ± S.E., Change in membrane potential was 
normalized to hyperpolarization by NA (30 μM) before treatment with the test compound. 
D, Weak depolarization in the presence of idazoxan (1 μM). E, Dose response of 
depolarization by NA in the presence of idazoxan. 
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Fig. 2.13 Inward rectifier potassium channels activated by NA 
A, Response to a series of 100 ms current steps (in 20 pA increments, −200–0 pA) in the 
absence (left) or presence (right) of NA. B, IV relationship obtained by current steps. C, 
Reversal potential at different extracellular potassium concentrations. D, The effects of 
Ba2+, which is an inhibitor of inward rectifier potassium channel. E, Dose- dependent 
inhibition of NA-induced hyperpolarization by Ba2+. Mean ± S.E., *: p  0.05.  
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2.3.6. The mechanism of activation of orexin neurons by NA 
 In the previous section, we showed that NA showed a weak depolarizing effect 
mediated by alpha 1 receptor activation (Fig. 2.12). The detailed mechanism of 
depolarization by NA (30 μM) was evaluated. 
In voltage clamp conditions (-60 mV), NA dose dependently activated inward 
current. Emax and EC50 were 165.6 ± 5.2 pA and 10.7 ± 0.7 μM (n = 6), respectively. 
Inward current was suppressed by pre-treatment with prazosin, a 1AR selective 
antagonist. Prazosin inhibited NA-induced inward current to 45.2% ± 9.0% (0.01 μM 
prazosin, n = 6) and 4.8% ± 1.9% (0.1 μM prazosin, n = 6) of control levels. On the other 
hand, phenylephrine, a selective 1AR agonist, mimicked inward current produced by 
NA. The size of the inward current was 16.0% ± 2.2% (10 μM, n = 7) and 46.6% ± 6.1% 
(100 μM, n = 7) of that induced by 30 μM NA. 
 To clarify downstream pathways from 1AR activation, activation of ion 
channels was analyzed (Fig. 2.15). NA (30 μM) caused strong inward current in the 
absence of extracellular Ca2+ ions (composition of extracellular solution, mM: 140 NaCl, 
2 CsCl, 1 MgCl2, 1 EGTA, 10 HEPES, and 10 glucose), suggesting NA activates ion 
channels which are inhibited by extracellular Ca2+ ions. The reversal potential of NA 
using CsCl intracellular solution was 4.5 ± 1.4 mV (n = 5), which is near the estimated 
value for non-selective cation channels. The activation of inward current was inhibited by 
SKF96365 (3 μM, 74.4% ± 5.8%, 30 μM, 28.6% ± 5.3% of control levels.), which is an 
inhibitor of non-selective cation channel. 
 Based on these results, NA activates orexin neurons via 1ARs and 
non-selective cation channels expressed in orexin neurons. 
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Fig. 2.14 NA-induced inward current in orexin neurons via α1ARs 
A, Voltage clamp recording at holding potential at −60 mV. B, Dose relationship of 
NA-induced inward current. C, D, Inhibition of inward current by prazosin. E, F, 
Phenylephrine-induced inward current in orexin neurons in a dose-dependent manner. 
Mean ± S.E. n = 6–7. 
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Fig. 2.15 Activation of non-selective cation channels by NA 
A, B, The effect of the removal of Ca2+ ions from the extracellular solution. C, Ramp 
protocol for analysis of the IV relationship. D, IV relationship in the control and NA (30 
μM)-containing condition. E, F The effect of the non-selective cation channel inhibitor, 
SKF96365, on inward current. Mean ± S.E., n = 7. 
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2.3.7. The effect of NA on calcium currents 
 To examine the effect of NA on Ca2+ current, Ca2+ current in whole cell patch 
clamp mode was measured. To measure Ca2+ current, Ca2+ ions in the extracellular 
solution were substituted with Ba2+ to enhance conductance. AP-5 (50 μM), CNQX (20 
μM), picrotoxin (100 μM), and TTX (1 μM) were added to the extracellular solution to 
block postsynaptic currents and action potentials.  
 Voltage ramps from −60 mV to 40 mV for 2 s induced −258.9 ± 26.0 pA (n = 6) 
of inward current. NA (100 μM) decreased Ba2+ current by 197 ± 19.0 pA (n = 6), (P < 
0.001, ANOVA).  
These data suggest that NA inhibits Ca2+ channels expressed in orexin neurons. 
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Fig. 2.16 inhibition of Ca2+ channel current by NA 
A, Ca2+ channel current obtained by ramp from -60 mV to 40 mV for 2 sec. To isolate 
Ca2+ channel current from other currents, AP-5 (50 μM), CNQX (20 μM), picrotoxin (100 
μM), and TTX (1 μM) were added to the extracellular solution. Decline in amplitude of 
Ca2+ channel current. Cd2+ and Ni2+ were added to confirm Ca2+ channel current. 
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2.4 Discussion 
In this study, the basic electrophysiological properties of orexin neurons were 
clarified using orexin/EGFP mice. The activity of orexin neurons was suppressed by 
muscimol, which is a GABAA receptor agonist, NA, and serotonin. Serotonin-induced 
hyperpolarization was mimicked by the serotonin 1A receptor agonist 8-OH-DPAT and 
inhibited by the serotonin 1A receptor selective antagonist WAY-100635. NA-induced 
hyperpolarization was mimicked by the α2AR agonist idazoxan and inhibited by the 
α2AR antagonist UK-14304. In the presence of idazoxan, NA activated orexin neurons 
via the α1 adrenergic receptor. On the other hand, the activity of orexin neurons was 
activated by glutamic acid and cholinergic agonist CCh. AMPA and NMDA receptors are 
involved in glutamate-induced activation. As the downstream pathway of these receptors, 
serotonin 1A receptors and α2ARs activated GIRK, and α1ARs activated NSCC. α2AR 
also activated Ca2+ channels. These results are summarized Fig. 2.18. 
The author used orexin/EGFP mice to identify orexin neurons before patch 
clamp experiments. Orexin neurons are sparsely distributed in the lateral hypothalamic 
area. Basic electrophysiological properties were not different from non-orexin neurons 
located in LHA. Thus, identification of orexin neurons using orexin/EGFP mice is an 
effective method to identify orexin neurons and evaluate the effects of neurotransmitters 
on these neurons. 
Serotonin strongly hyperpolarized orexin neurons. In this study, receptors were 
identified using selective agonists, antagonists, and immunohistochemistry using 
antibodies. 8-OH-DPAT has agonistic activity for serotonin 1A and serotonin 7 
receptors [32]. On the other hand, WAY-100635 is a serotonin 1A receptor-selective 
antagonist. Serotonin activates GIRK potassium channels, which are regulated via 
Gi-coupled GPCRs. Serotonin 7 receptors are known to be Gs-coupled GPCRs. Based 
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on our results, serotonin 1A receptors have a major role in serotonergic regulation of 
orexin neurons. However, several studies showed that serotonin 1A receptors and 
serotonin 7 receptors make heterodimers and crosstalk in downstream signaling [33]. 
There is the possibility of involvement of serotonin 7 receptors in serotonergic 
signaling. 
NA, adrenaline, and DA hyperpolarized orexin neurons. However, the IC50 was 
different between NA/adrenaline and DA. A high concentration of DA activates α2ARs 
[34]. The hyperpolarization could be mediated by activation of the adrenaline receptor. 
In this study, we found strong hyperpolarization via α2ARs and weak depolarization via 
the alpha 1 receptor. Alpha 1-mediated suppression is a major effect because 
depolarization was not observed in the absence of the α2AR antagonist idazoxian. 
However, there is the possibility that these neurons receive different inputs between 
synapses containing α2AR and α2AR. We found Ca2+ channels were inhibited by NA. 
Ca2+ channels in synaptic terminals have important roles in the secretion of 
neurotransmitters. NA can suppress the release of orexin from orexin neurons. 
 The activity of orexin neurons is associated with sleep/wake state. Activation 
of orexin neurons leads to wakefulness. The receptors expressed in orexin neurons are 
related to sleep/wake state. GABAA receptor modulators such as BZD drugs promote 
sleep [35]. Serotoinin 1A receptor agonists, such as tandospirone, cause sleep [36]. The 
α2AR agonist dexmedetomidine causes sedation [37]. The α1AR antagonist prazosin is 
reported to ameliorate sleep disorder [38]. The modulation of orexin neurons by 
serotonergic and adrenergic receptors is consistent with their role as modulators in 
human.  
 Serotonin and noradrenaline are decreased by stress and aging caused by 
environmental changes. This suppressive effect of serotonin and noradrenaline for 
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orexin neurons indicates that these neurotransmitters have sleep-promoting effects, and 
reduction of these neurotransmitters can inhibit sleep. The results of this study indicate 
that reduction of serotonin and noradrenaline can suppress wake-promoting orexin 
neurons.  
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Fig. 2.17 Summary of receptors and ion channels identified in orexin neurons 
Orexin neurons were suppressed via GABAA, α2AR, and serotonin 1A receptors and 
activated by AMPA, NMDA, muscarinic, and α1ARs. 
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Chapter 3 The importance of the regulation 
of orexin neurons by sleep/wake 
homeostasis-related pathways 
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3.1 Introduction 
 In Chapter 2, the regulation of orexin neurons by neurotransmitters was 
evaluated. These results suggested that orexin neurons are regulated by neurotransmitters 
such as glutamate, GABA, serotonin, NA, and acetylcholine. Stress and aging, which are 
affected by environmental changes, are related to the neurotransmitters serotonin and 
noradrenaline that suppressed the activity of orexin neurons. In Chapter 3, the author will 
focus on the physiological importance of the effect of neurotransmitters in sleep/wake 
homeostasis. 
 The transition from wake to sleep is mediated by GABAergic and 
monoaminergic/serotonergic systems. The orexin system stabilizes the waking state by 
activation of the monoaminergic cholinergic system.  
GABA neurons located in the ventrolateral preoptic area (VLPO) are considered 
as inducers of sleep [39]. The firing pattern of VLPO GABA neurons is sleep active. 
VLPO neurons project their axons into wake active nuclei such as the histaminergic 
tuberomamillary nucleus (TMN), serotonergic dorsal and medial raphe nuclei, 
cholinergic laterodorsal tegmental nucleus (LDT)/ pedunculopontine nucleus (PPN) and 
adrenergic locus coeruleus (LC). GABA neurons promote sleep via suppression of the 
activity of monoaminergic/cholinergic neurons. 
 Serotonergic neurons are located in the midbrain dorsal and medial raphe nuclei. 
Neurons in both regions are active in the waking state. The dorsal and medial raphe nuclei 
have ascending projections to the cerebral cortex, limbic system, and basal ganglia. 
Orexin neurons activate serotonergic dorsal and medial raphe neurons via the activation 
of orexin 1 and 2 receptors [40] [41]. Raphe serotonergic neurons show wake-active 
properties. 
 Noradrenergic neurons in the LC are considered to have an important role in 
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sleep/wake homeostasis. LC adrenergic neurons are activated by OX1R. LC adrenergic 
neurons show wake active properties and innervate the neocortex. Inhibition of LC 
adrenergic neuron via optogenetic methods causes the induction of sleep. 
 Histaminergic and cholinergic neurons in the LDT/PPN are also activated in 
the waking period [39]. Orexin activates both cholinergic and histaminergic neurons 
[42] [43].  
 The response of orexin neurons to GABA, NA, and serotonin suggests that 
orexin neurons receive innervation from these neurotransmitter-containing neurons. In 
this chapter, the presence of physiological input pathways for orexin neurons via GABA, 
serotonin, and NA is evaluated. The input from GABA neurons was evaluated by the slice 
patch clamp method. The presence of noradrenergic and serotonergic inputs was 
evaluated by immunohistochemistry. Moreover, in vivo pharmacological studies were 
conducted to clarify the physiological importance of serotonergic input pathways for 
orexin neurons. The physiological importance of GABAergic, serotoninergic, and 
noradrenergic inputs is discussed using obtained experimental results and literature 
information.  
 
3.2 Materials and methods 
3.2.1 Recording of postsynaptic current 
Postsynaptic currents were recorded using a sodium channel blocker QX-314 (1 
mM)-containing pipette to suppress action potentials in recorded neurons. TTX (1 μM) 
was added to measure miniature postsynaptic currents. Excitatory postsynaptic current 
was measured by adding picrotoxin (100 μM) and inhibitory postsynaptic current was 
measured by adding AP-5 (50 μM) and CNQX (20 μM). To measure evoked postsynaptic 
current, electrical stimuli (100-200 μA, 0.1 msec, 0.1 Hz) were generated using a bipolar 
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stimulation electrode placed in the LHA. 
 
3.2.2. Immunohistochemistry 
Adult male C57BL/6J mice (20–25 gm; Charles River Laboratories, Kanagawa, 
Japan) were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and perfused 
sequentially with 10 ml of saline and 20 ml of 4% paraformaldehyde in 0.1 M phosphate 
buffer for 20 min. The brains were removed, trimmed, and immersed in the same fixative 
solution for 12 hr and then immersed in 30% sucrose solution for 2 d at 4°C. The brains 
were quickly frozen in embedding solution with OCT compound (Sakura Finetechnical, 
Tokyo, Japan). The frozen brains were cut into 40-μm-thick coronal sections on a cryostat 
(MICROM HM 500; MICROM International, Walldorf, Germany). These slices were 
washed in Tris-buffered saline (TBS) containing 0.25% Triton X-100 (TBS-TX) and 
incubated in 1% bovine serum albumin fraction V in TBS-TX for 30 min. For orexin and 
serotonin transporter double staining, sections were incubated with rabbit anti-orexin 
antiserum (1:2000) [44] and goat anti-serotonin transporter antiserum (1:100) (Santa 
Cruz Biotechnology, Santa Cruz, CA) for 24 hr at 4°C. Sections were then incubated with 
Cy3-labeled donkey anti-goat IgG antibody (1:800; Molecular Probes, Eugene, OR) for 1 
hr at room temperature and with fluorescein isothiocyanate-labeled donkey anti-rabbit 
IgG (1:800; Molecular Probes) for 1 hr at room temperature. For orexin and serotonin 1A 
receptor double staining, sections were incubated with rabbit anti-orexin antiserum 
(1:2000) [44] and guinea pig anti-serotonin 1A receptor antiserum (1:1000) (Chemicon, 
Temecula, CA) for 48 hr at 4°C. These sections were simultaneously incubated with 
Alexa 488-labeled goat anti-rabbit IgG antibody (1:800; Molecular Probes) and with 
Alexa 594-labeled goat anti-guinea pig IgG (1:800; Molecular Probes) for 1 hr at room 
temperature. The sections were mounted and examined with a fluorescence microscope 
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(AX-70; Olympus Optical). To confirm the specificity of antibodies, incubations without 
primary antibody were conducted as a negative control in each experiment, and no signal 
was observed.  
 
3.2.3. Intracerebroventricular administration  
Male C57BL/6J wild type mice (20–25 g; Charles River Laboratories) or 
orexin/ataxin-3 hemizygous mice (25–27 g, N7 backcross to C57BL/6J) were housed 
under controlled lighting (12 hr light/dark cycle; lights on from 8:00 A.M. to 8:00 P.M.) 
and temperature (22°C) conditions. Food and water were available ad libitum. Mice were 
anesthetized with pentobarbital (50 mg/kg, i.p.) and positioned in a stereotaxic frame 
(David Kopf Instruments, Tujunga, CA), and a guide cannula was implanted into the third 
ventricle under sterile conditions. Mice were then housed separately for a recovery period 
of at least 7 d. The position of the cannula was verified by central administration of 
human neuropeptide Y (0.3 nmol in sterile water) to test for a positive response. Mice that 
ate at least 0.5 g of food over a 1 hr period after injection were used for experiments. 
WAY100635, a serotonin 1A receptor antagonist, was delivered in saline at a volume of 3 
μl over 60 sec, and the injector was left in position for an additional 60 sec to ensure 
complete dispersal of the drug. Saline alone was injected in the vehicle control 
experiment. Intracerebroventricular injection was initiated at 7:30 P.M. and was 
completed by the end of the light period (8:00 P.M.). The locomotor activity of individual 
mice during the dark period after intracebroventricular injection was assessed with an 
infrared activity monitor (Supermex; Muromachi Kikai, Tokyo, Japan) in Plexiglas cages 
to which mice had been well habituated. The chambers were light-controlled (12 hr 
light/dark cycle; lights on from 8:00 A.M. to 8:00 P.M.) and were sound-attenuated. The 
infrared activity monitor was a sensor mounted above the cage to detect changes in heat 
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across multiple zones of the cage through an array of Fresnel lenses.  
 
3.2.4 Statistical analysis 
Data were analyzed by two-way ANOVA followed by post hoc analysis of 
significance by Fisher's protected least significant difference test using the Stat View 4.5 
software package (Abacus Concepts, Berkeley, CA). p values less than 0.05 were 
considered statistically significant.  
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3.3 Results 
3.3.1. The excitatory and inhibitory input to orexin neurons 
In slice preparations, the synaptic input to orexin neurons can be measured. To 
determine whether orexin neurons actually received glutamatergic or GABAergic input 
in the brain, spontaneous excitatory postsynaptic current (EPSC) and inhibitory 
postsynaptic current (IPSC) were recorded. EPSC was measured using extracellular 
solution containing bicuculline (50 μM) to suppress IPSC, and IPSC was measured 
using extracellular solution containing AP-5 (50 μM) and NBQX (50 μM) to suppress 
EPSC. Membrane potential was held at −30 mV in voltage clamp condition. 
Under this condition, spontaneous EPSC and IPSC were observed. 
Simultaneous application of AP-5 (50 μM), NBQX (50 μM), glutamate receptor 
antagonists, and bicuculline (50 μM), a GABAA receptor antagonist, largely blocked 
EPSCs and IPSCs (Fig. 3.1).  
These results suggest that orexin neurons receive glutamatergic excitatory and 
GABAergic inhibitory input in the brain. 
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Fig. 3.1 Spontaneous PSC in orexin neurons  
Membrane potential was set at −30 mV. EPSC and IPSC were completely blocked by 
treatment with bicuculline (50 μM), NBQX (50 μM) and AP-5 (50 μM). EPSC and IPSC 
were recovered by removal of inhibitors. 
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3.3.2. TH-ir neurons are in apposition to orexin-ir neurons 
 Immunohistological analysis was conducted to understand the distribution of TH 
immunoreactive axons. The majority of orexin-ir neurons were located within a field of 
dense TH-ir axons. TH-ir varicosities were closely opposed to orexin-ir cell bodies and 
TH-ir axons appeared to be located adjacent to orexin-ir neurons (Fig. 3.2).   
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Fig. 3.2 TH-ir nerve endings in the lateral hypothalamic area 
A, Immunoreactivity for orexin neurons (brown) and TH (black). B, C Magnified view 
marked in A. Arrowheads indicate varicosities which are localized near the orexin 
neurons. Scale bar, 20 μm  
  
A B 
C 
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3.3.3. The influence of NA on excitatory and inhibitory synaptic inputs 
 Because TH-ir neurons were observed in the lateral hypothalamic area, the 
possibility for the modulation of synaptic inputs of orexin neurons by NA was evaluated. 
Postsynaptic current was measured using QX-314 (1 mM)-containing intracellular 
solution to suppress action potentials in orexin neurons. Spontaneous excitatory 
postsynaptic current (sEPSC) was measured in the presence of picrotoxin (100 μM) to 
suppress IPSC and spontaneous inhibitory postsynaptic current was measured in the 
presence of AP-5 (50 μM) and CNQX (20 μM) to suppress EPSC (Fig. 3.3). NA (30 μM) 
application significantly decreased sEPSC frequency to 38.2% ± 6.7% of control values 
(n = 6, P < 0.0001, ANOVA). sEPSC frequency recovered partially after NA washout. 
Reduction of sEPSC by NA was abolished by pre-treatment of idazoxan, antagonist for 
α2AR (1 μM, n = 6, P < 0.05). On the other hand, NA increased IPSC frequency by 
398.1% ± 78.6% (n = 6, P < 0.0001). Spontaneous inhibitory postsynaptic currents 
(sIPSC) amplitude was also increased by 340% ± 100% (n = 6) of control value. The 
increase in sIPSCs was abolished in the presence of the α1-AR antagonist prazosin (1 μM, 
n = 6, P < 0.0001, ANOVA) 
To reveal the role of adrenergic receptor expression in the presynaptic terminal, 
the effect of NA on the miniature excitatory postsynaptic current (mEPSC)s and 
miniature inhibitory postsynaptic current (mIPSC)s were studied in the presence of TTX 
(1 μM) (Fig. 3.4). NA decreased mEPSC frequency to 38.5% ± 8.9% of control levels (n = 
6, P < 0.001, ANOVA). In contrast to the effect on sIPSCs, NA decreased mIPSC 
frequency to 32.6% ± 4.1% of control levels (n = 7, P < 0.0001, ANOVA) (Fig. 3.3, B–D). 
Reduction of mEPSCs or mIPSCs was suppressed in the presence of idazoxan (1 μM).  
The role of presynaptic adrenergic receptors was also evaluated using evoked 
excitatory postsynaptic current  (eEPSC) and evoked inhibitory postsynaptic current 
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(eIPSC), generated by electrical stimuli (100–200 μA, 0.1 ms, 0.1 Hz) using bipolar 
stimulation electrodes placed within the LHA (Fig. 3.5). Recordings were conducted 
under voltage clamp condition (−60 mV). In the presence of picrotoxin (100 μM), 
eEPSCs with an amplitude of 226.0 ± 22.6 pA (n = 5) were recorded. NA (30 μM) 
reduced the eEPSC amplitude to 41.3% ± 8.0% (n = 5, P < 0.0001, ANOVA) compared 
to values before NA application. eEPSCs recovered within 10–18 min after NA washout. 
Recovered eEPSCs were completely abolished by co-application of AP-5 (50 μM) and 
CNQX (20 μM) in the bath solution, which suggests that they were attributable to the 
activation of ionotrophic glutamate receptors. In the presence of AP-5 (50 μM) and 
CNQX (20 μM), we observed eIPSCs with an amplitude of 589.8 ± 277.7 pA (n = 5). NA 
application decreased the eIPSCs to 27.8% ± 10.9% (n = 5) as compared to values before 
application. eIPSCs partially recovered after NA washout.  
Based on these results, NA can suppress the activity of orexin neurons via 
indirect mechanisms. NA activated GABAergic neurons innervating orexin neurons via 
alpha 1 receptors and suppressed glutamatergic neurons innervating orexin neurons. 
Synaptic transmission to orexin neurons was suppressed by α2AR. 
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Fig. 3.3 Reduction of sEPSC and induction of sIPSC by NA 
A, Reduction in frequency of sEPSC. B, Induction of sIPSC. C, The effect of idazoxan on 
sEPSC reduction D, The effect of prazosin on sIPSC induction by NA. PSC frequency 
was normalized to basal PSC frequency. Mean ± S.E., n = 6, *: p ≤ 0.05  
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Fig. 3.4 Reduction of mEPSCs and mIPSCs by NA 
A, B: Reduction of mEPSCs and mIPSCs by NA. C and D: Summaries of the data in A 
and B, respectively. Frequency of PSCs were normalized to the frequency before NA 
treatment. Data are means ± S.E. *, p ≤ 0.05, ANOVA. Wash, washout. 
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Fig. 3.5 The effect of NA on eEPSC and eIPSC 
A, B, Inhibition of eEPSC by NA (30 μM). C, Time course of NA-induced inhibition of 
eEPSC. D, E, Inhibition of eIPSC by NA. Traces represent the mean of ten recordings. 
Mean ± S.E. n = 5, *: p  0.05.  
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3.3.4. Orexin-ir neurons are in apposition to serotonin transporter-ir nerve endings 
 To determine whether serotonergic neurons innervate orexin neurons, sections of 
hypothalamus were double stained immunohistochemically for serotonin transporter, 
which is expressed in serotonergic presynaptic membranes, and orexin.  
  Serotonin transporter-ir nerve endings were observed in the LHA (Fig. 3.6). 
The nerve endings were distributed near the somata and dendrites of orexin-ir neurons. 
All orexin-ir neurons were surrounded by serotonin transporter-ir nerve endings. 
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Fig. 3.6 Serotonin transporter-ir nerve ending in the lateral hypothalamic area 
A, Immunoreactivity for orexin (fluoresceinisothiocyanate (FITC), green). B, 
Immunoreactivity for serotonin transporter (red, Cy3). C, D, The merged image. D, 
Magnified view marked in C. Arrowheads indicate varicosities located near orexin-ir 
neurons. 
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3.3.5. Modulation of locomotor activity by serotonin 1A receptor antagonists in 
wild type mice and orexin-neuron-deficient mice 
To understand the physiological importance of serotonergic inhibitory inputs to 
orexin neurons, the serotonin 1A receptor antagonist WAY-100635 was injected into the 
third ventricle of wild type mice and orexin-neuron-deficient orexin/ataxin-3 mice. 
WAY-100635 increased locomotor activity in wild type mice in the late dark 
phase (Fig. 3.7). On the other hand, the increase was not observed in orexin/ataxin-3 mice. 
The activation of orexin neurons can increase locomotor activity. These results suggest 
that inhibitory input for orexin neurons by serotonergic neurons exists in the late dark 
phase. 
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Fig. 3.7 The effect of the serotonin receptor antagonist on locomotor activty 
A, Locomotor activity after administration of a serotonin 1A receptor antagonist into the 
third ventricle in wild type mice. B, Locomotor activity in orexin/ataxin-3 mice. Values 
are mean ± S.E. 
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3.4. Discussion 
 In this chapter, we showed that glutamatergic and GABAergic input was 
observed in orexin neurons by electrophysiological study of slice samples. Serotonergic 
and adrenergic nerve terminals were observed in the lateral hypothalamic area near the 
orexin neurons. NA increased the frequency of IPSC via α1AR and decreased the 
frequency of EPSC via α2AR. α2AR suppressed the release of glutamate and GABA in 
synaptic terminals innovating orexin neurons. Inhibition of serotonergic input increased 
spontaneous locomotor activity. The increase was not observed in 
orexin-neuron-deficient mice. Experimental results are summarized in Fig. 3.8.  
This study confirmed the presence of GABAergic, serotonergic, and adrenergic 
input to orexin neurons. For further understanding of sleep/wake homeostasis, 
information about the origin is important. In one study, transgenic mice that express a 
fusion protein between the nontoxic C-terminal fragment of tetanus toxin (TTC) and 
GFP (TTC::GFP) exclusively in orexin neurons, acting as a retrograde tracer, were used 
to identify the origin of inputs [45]. Based on this retrograde tracer study, orexin 
neurons receive input from GABAergic sleep active neurons and medial raphe 
serotonergic wake active neurons.  
GABAergic neurons in the rostral hypothalamic area, especially VLPO, are 
known as sleep promoting neurons. A study using neuronal unit recording showed that 
VLPO neurons are active during sleep. A recent study showed that sleep deprivation 
increases the amplitude of GABA-induced hyperpolarization in orexin neurons. 
GABAergic input plays an important role in sleep promotion via suppression of orexin 
neurons.  
A study using TTC::GFP mice showed that orexin neurons receive serotonergic 
innervation from the medial raphe nucleus. The dorsal raphe nucleus projects to the 
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medial raphe nucleus. Because serotonin neurons in the raphe nucleus are wake-active, 
inhibitory input from the medial raphe can contribute to negative feedback to stabilize the 
activity of orexin neurons in the waking state and transition to sleep state. Serotonin 1A 
receptor overexpression in orexin neurons causes increased slow wave sleep. By these 
results, suppression of orexin neurons by activation of serotonin 1A receptor can promote 
sleep [46]. 
A study using TTC::GFP mice showed that there is not clear evidence of 
synaptic innervation for orexin neurons by adrenergic neurons in the locus coeruleus. 
However, NA inhibited orexin neurons not only directly but also indirectly via activation 
of GABAergic and glutamatergic interneurons in an indirect feedback loop from 
adrenergic neurons to stabilize sleep/wake homeostasis. 
The hypothesis based on this study and the literature is shown in Fig. 3.9. 
Orexin neurons receive direct inhibitory input from serotonergic neurons in the median 
raphe nucleus (MnR) and direct/indirect inhibitory input from the LC. A closed loop 
between orexin neurons and serotonergic and adrenergic systems can exist. This loop 
can contribute to sleep wake homeostasis. Modulation of input pathways to orexin 
neurons can be a method to induce sleep. 
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Fig. 3.8 Summary of results in chapter 3 
Glutamatergic and GABAergic neurons innervate orexin neurons. Neuronal terminals of 
serotonin neurons are observed near the orexin neurons in the LHA. Neuronal terminals 
and varicosities of adrenergic neurons were observed in the LHA.  
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Fig. 3.9 Feedback loop between orexin and serotonin/NA neurons 
Orexin neurons activate dorsal raphe serotonin neurons via orexin 1 and 2 receptors and 
serotonergic inhibitory input from the medial raphe nucleus. Orexin neurons activate 
adrenergic neurons in the LC via OX1R and receive inhibitory input in a direct/indirect 
manner from the adrenergic system. Orexin neurons receive GABAergic input from 
sleep-promoting VLPO GABA neurons.  
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Chapter 4 The possible treatment of sleep 
disorders via regulation of input pathways for the 
orexin system 
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4.1 Introduction 
In the previous chapters, the suppressive effect of NA and serotonin on orexin 
neurons and receptors involved in this response were identified. Moreover, the 
physiological importance of serotonergic and adrenergic inhibition of the orexin system 
in sleep/wake homeostasis was examined using a preclinical method. The information 
about receptors expressed in orexin neurons can provide information for the 
understanding of the mechanism of sleep-promoting compounds and discovery of 
sleep-promoting methods. 
For treatment of patients with insomnia, a general sleep disorder, drugs that 
suppress wake/active neurons are widely used. There are three categories of 
anti-insomnia drugs: GABA receptor modulators, melatonin receptor agonists, and 
orexin receptor antagonists. While GABAA modulators have strong sleep-promoting 
effects, several kinds of side effects are observed because GABAA receptors are 
expressed in wide areas of the brain and neuronal pathways that are not involved in 
sleep/wake homeostasis. In 2006, a melatonin receptor antagonist was approved. The 
melatonin pathway can cause promotion of sleep. Moreover, an orexin receptor 
antagonist was approved. The orexin receptor antagonist is considered an effective 
treatment method for insomnia because the mechanism is based on modulation of the 
physiological sleep/wake pathway. 
Non-drug treatment can be considered as important for the treatment of 
insomnia because insomnia is chronic disease and side effects can be a problem for aged 
patients. There are several kinds of natural products which are known to have 
sleep-promoting effects in humans. For example, 5 kanpo medicines have indications 
for insomnia. In Europe, several kinds of herbs have been used for the treatment of 
insomnia based on long-term experience of human use. The author identified that orexin 
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neurons are inhibited by GABAA receptors, serotonin 1A receptors, and α2AR. In this 
chapter, database analysis was conducted to evaluate the possibility for modulation of 
orexin neurons by natural products. Based on the collected information, the author 
discusses the possibility for the development of new treatment methods for insomnia via 
the orexin system and possible new treatment methods are discussed. 
 
4.2. Materials and methods 
 Target molecules of natural products written in guidelines for sleep disorder 
were examined using literature information. The active component and their chemical 
structure were examined using the PubChem and Pubmed database.  
 
4.3 Results 
4.3.1 The natural products used for treatment of insomnia 
 Natural products that are used to modulate sleep disorders and can modulate 
receptors expressed in orexin neurons are shown in Table 4.1. Valerian is used as an 
herbal medicine in Europe. Extracts of this root show improvement in insomnia in 
human experience. The active component is considered to be valerenic acid. Valerenic 
acid can activate GABAA receptors. Kava is the dry root extract of Pioer methysticum. 
Kava has been used for the treatment of insomnia by human experience. The active 
component is considered to be Kavain, which activates GABAA receptors. 
In Chinese and Japanese herbal medicine, kanpo has an indication for insomnia. 
Yoku-kan-san and Suan Zao Ren Tang also have indications for insomnia based on 
long-term experience in human use. Yoku-kan-san is made by seven kinds of herbs. 
Uncaria Hook, which is hook of Uncaria rhynchophylla, is considered to have an 
important role in sleep-promoting effects and the main component, Geissoschizine 
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methyl ether, can activate serotonin 1A receptors. Suan Zao Ren Tang contains the seed 
of Zizyphus jujube Mill var, which contain sanjoine A as an active component. GABAA 
receptors and serotonin 1A receptors are activated by extract from the seeds of Zizyphus 
jujube Mill var. 
Rosemary is considered to improve insomnia by human experience. 
Rosmarinic acid is considered the active component. Rosmarinic acid activates the 
GABAergic pathway in preclinical models. 
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Table 4.1 Natural products modulating sleep/wake homeostasis 
Name of plant Name as herbal 
medicine 
Possible active 
compound 
Possible mechanism 
Valeriana 
officinalis L. 
Valerian Valerenic acid 
 
Activation of GABAA 
receptors 
[47] 
Piper 
methysticum 
Kava Kavain 
 
Activation of GABAA 
receptors[48] 
Uncaria 
rhynchophylla 
Yoku-kan-san Geissoschizine methyl 
ether 
 
Activation of serotonin 
1A receptors[49] 
Zizyphus jujube 
Mill var. spinosa 
Suan Zao Ren 
Tang 
 
Sanjoinine A 
 
Activation of serotonin 
1A receptors 
Activation of 
GABAergic pathway 
[50] 
Perilla frutescens Rosmarinic acid Rosmarinic acid 
 
Activation of 
GABAergic pathway 
[51] 
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4.3.2 The effects of natural products for insomnia 
 The clinical study of natural products for insomnia is summarized in Table 4.2. 
Preclinical studies of natural products are summarized in Table 4.3. The effect of 
valerian on insomnia was confirmed by a two-week clinical study. Valerian improved 
sleep quality in insomnia patients. In a preclinical study, a single administration of 
valerian shortened sleep latency in rodents. Kava (200 mg) improved insomnia after 4 
weeks of treatment in humans. In rodents, Kava shortened sleep latency after a single 
administration. Yoku-kan-san increased the total amount of sleep time in humans. In 
rodents, the induction of sleep was reported after a single administration. Suan Zao Ren 
improved sleep quality in patients treated with methadone. Rosmarinus officinalis 
increased sleep time in opiate-withdrawal patients. In rodents, rosmarinic acid shortened 
sleep latency. 
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Table 4.2 Clinical trials of natural products for insomnia 
Herbal 
medicine 
Study design Treatment 
period 
Result 
Valerian 
 
Valerian vs. placebo  4 weeks Improvement of sleep quality 
[52] 
Kava Kava vs. placebo 4 weeks Improvement of sleep quality 
score 
[52] 
Yoku-kan-san Yokukan-san vs. 
Anchu-san 
3 days Increase of total sleep time[15] 
Suan Zao Ren 
Tang 
 
1. Placebo 
2. Suan Zao Ren  
(n = 45) 
(during methadone 
treatment) 
4 weeks Improvement of sleep score 
Average sleep efficiency 
[53] 
Rosmarinus 
Officinalis 
Opiate withdrawal 
syndrome patients 
14 days Increased sleep time 
[54] 
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Table 4.3 Preclinical studies of the effects of herbal medicine on insomnia 
Natural 
products 
Study Model Treatment period Result 
Valerian 
 
Sleep 
disturbed rat 
Single 
administration 
(1000 mg/kg) 
Shortening in sleep latency [55] 
Kava Sleep 
disturbed rat 
Single 
administration 
(1000 mg/kg) 
Shortening in sleep latency [56] 
Yoku-kan-san Normal mice Single 
administration 
(300 mg/kg) 
Sleep promotion (reduction by 
skin temperature) 
[57] 
Sanjoinine A Pentobarbital 
induced 
sleep model 
Single 
administration of 
sanjoinine A (2 
mg/kg) 
Shortening in sleep latency 
[58] 
Rosmarinic 
acid 
Pentobarbital 
induced 
sleep model 
Single 
administration 
(0.5–2 mg/kg) 
Shortening in sleep latency 
Increase of total sleep time 
[51] 
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4.3.3 The relationship between the mechanism of insomnia-modulating natural 
products and orexin neuron modulation 
Based on the expression of receptors in orexin neurons analyzed in Chapter 2 
and the information for target pathways of natural products that can ameliorate insomnia, 
possible effecst on orexin neurons are shown in Fig. 4.2.  
Varelian, KAVA, Suan Zao Ren Tang, and rosmarinic acid can suppress the 
activity of orexin neurons via activation of the GABAergic pathway. Suan Zao Ren 
Tang and Yoku-kan-san can activate serotonin 1A receptors and suppress activity of 
orexin neurons. In the sleep-promoting effect of these herbal medicines, suppression of 
orexin neurons may be one of possible mechanism. Rosmarinic acid also suppresses 
orexin neurons via increased synthesis of noradrenaline [24]. 
The analysis of properties of orexin neurons can provide information which can 
be useful for understanding the mechanisms of herbal drugs for sleep/wake disorders. 
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Fig. 4.1 Possible modulation of orexin neurons via herbal medicines that ameliorate 
sleep/wake disorders 
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4.4 Discussion 
 In this chapter, the possible regulation of orexin neurons by herbal medicines 
known to modulate sleep/wake homeostasis was examined. Moreover, based on the 
mechanism of the approved orexin receptor antagonist drug and the herbal medicine, 
combination therapy could be an effective treatment method for insomnia. 
The effect of herbal medicine was mainly identified by human use. Moreover, 
anti-insomnia effects can be evaluated using pre-clinical models. Natural products 
showing an anti-insomnia effect in humans would show sleep promoting effects in 
rodent models.  
Combination therapy using drugs with different mechanisms of action is useful 
because of additive or synergistic effects. Now, an orexin receptor antagonist is 
approved as an anti-insomnia drug. The combined use of the orexin receptor antagonist 
and natural products that are expected to modulate orexin neurons could provide 
effective treatment methods for insomnia (Fig. 4.2). 
Valerian, KAVA, Suan Zao Ren Tang, and rosmarinic acid are reported to 
modulate GABAA receptors. In our experimental data, we showed that orexin neurons 
express functional GABAA receptors. The combined use of those compounds and orexin 
receptor antagonists may be an effective treatment method for insomnia.  
Our study showed that serotonin suppressed the activity of orexin neurons via 
serotonin 1A receptors. A serotonin 1A receptor antagonist locally administrated to the 
hypothalamus increases locomotor activity in an orexin neuron-dependent manner. 
Combination therapy using orexin receptor antagonists and Yoku-kan-san could be an 
effective treatment method for insomnia. 
The activity of orexin neurons was suppressed by α2AR. In herbal medicine 
often used for insomnia, adrenergic alpha 2 receptor agonists were not observed. 
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However, activation of α2ARs has the potential to increase sleep time [59]. This 
information suggests that screening natural products for an effect on adrenergic 
receptors can lead to identifying new natural products with anti-insomnia effects.  
In this chapter, the possible modulation of orexin neuron activity by several 
herbal medicines with sleep-promoting effects was discussed. This information could 
contribute to future development of new approaches for the treatment of insomnia by 
combination therapy by approved orexin receptor antagonists and herbal medicine. 
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Fig. 4.2 The possibility of combination therapy using approved drugs and natural 
products as complementary medicine 
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Chapter 5 General conclusions 
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Insomnia is a common disease and the change in our environment provides risk 
factors such as aging, irregular work, and jetlag caused by internationalization. In this 
study, the author evaluated the responsiveness of orexin neurons to neurotransmitters. 
GABA, serotonin, and NA suppressed the activity of orexin neurons. The receptor 
subtype related to responses was identified using selective agonists and antagonists. The 
GABAA receptor, serotonin 1A receptor, and α2AR were involved in the suppression of 
orexin neurons. α1ARs are involved in the activation of orexin neurons although their 
impact was lower than that of α2AR. These experimental results were summarized in 
Chapter 1. 
 Sleep/wake homeostasis is regulated by the relationship between orexin 
neurons and monoaminergic, cholinergic, and GABAergic neurons. In Chapter 2, the 
author evaluated input pathways to orexin neurons from serotonergic, GABAergic, and 
adrenergic systems. In slice patch clamp experiments, GABAergic inputs to orexin 
neurons were observed. GABAergic input was increased by treatment with NA. By 
immunohistochemical analysis, the authors identified that serotonergic and 
noradrenergic neural fiber are apparent near orexin neurons in the LHA. Treatment with 
the serotonin 1A receptor selective antagonist in the third ventricle increased locomotor 
activity in wild type mice, and the effect was not observed in orexin/ataxin-3 mice. 
Orexin neurons receive physiological input from GABAergic, serotonergic, and 
adrenergic systems. The physiological role of these inputs was discussed based on the 
experimental data and literature information. Orexin neurons receive serotonergic input 
from the medial raphe nucleus and GABAergic input from the VLPO. In the induction 
of sleep, orexin neurons receive GABAergic input from other orexin neurons. The 
serotonergic and adrenergic inhibitory input can act as negative feedback pathway to 
stabilize the sleep/wake cycle. The importance of serotonergic input to orexin neurons 
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was confirmed by reported studies using orexin neuron-selective serotonin 1A 
receptor-overexpressing Tg mice. By overexpression of serotonin 1A receptor in orexin 
neurons, the duration of slow wave sleep was increased. Serotonergic input to orexin 
neurons has a sleep promoting effect. 
 In Chapter 4, the possible regulation of orexin neurons by natural products was 
discussed. Several natural products are known to modulate sleep/wake homeostasis and 
have been used for treatment of insomnia based on human experience. From the 
literature and public database information, valerianic acid and sanjoinin A promote sleep 
in humans via activation of GABAA receptors. Rosmarinic acid, which is a component 
of Perilla frutescens, activates GABAergic and NA pathways. Yoku-kan-san, which is a 
Chinese and Japanese herbal medicine, has been used to manage insomnia. 
Geissoschizine methyl ether, which has serotonin 1A receptor agonistic activity, has also 
been used. Seeds of the Zizyphus jujube Mill var. spinose, which are used to make Suan 
Zao Ren Tang, activate serotonin 1A receptors and the GABAergic pathway. 
Modulation of GABAergic, adrenergic, and serotonergic pathways for orexin neurons 
can modulate sleep/wake homeostasis in whole animals. Herbal medicines which 
activate GABA, NA, and serotonin pathways can modulate the activity of orexin 
neurons. 
 Sleep disorders are common, and complementary medicine, such as herbal 
medicine, is widely used. On the other hand, effective drugs based on a biological 
understanding of sleep/wake homeostasis have been developed such as orexin receptor 
antagonists. The author considers that combination therapy using approved drugs and 
complementary medicine could be an effective treatment method. Strong efficacy via 
combination of different drug mechanisms is expected. Moreover, adverse effects of the 
drug could be reduced by reduction of the dosage in combination therapy. The 
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combined use of herbal medicine that suppresses the activity of orexin neurons and 
orexin receptor antagonists is expected to have synergistic effects because of dual 
inhibition upstream and downstream in the same pathway. 
 In this study, the author used orexin/EGFP mice and identified the response of 
orexin neurons to neurotransmitters. By database searching, herbal medicines that affect 
receptors expressed by orexin neurons were listed. This information can be useful for 
understanding current treatment methods using herbal medicine and the development of 
future new treatment options for insomnia. 
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Summary 
 Orexin neurons are modulated by GABAergic, serotonergic, and noradrenergic 
pathways. These pathways have important roles in sleep/wake homeostasis. Several 
herbal medicines that are used for insomnia can affect GABAergic, serotonergic, and 
noradrenergic signaling. An understanding of the modulation of orexin neurons can be 
useful to understand the mechanism of action of herbal medicineis. Moreover, the 
information may contribute to the establishment of new treatment options for insomnia 
using approved drugs and herbal medicines.  
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